全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Snežana M. Bošnjak , Richard J. Gralla , Lee Schwartzberg
来源:[J].Supportive Care in Cancer(IF 2.649), 2017, Vol.25 (5), pp.1661-1671Springer
摘要:Chemotherapy-induced nausea (CIN) has a significant negative impact on the quality of life of cancer patients. The use of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists (RAs) has reduced the risk of vomiting, but (except for palonosetron) their effect on nause...
作者:Lee Schwartzberg , Bernardo Rapoport ...
来源:[J].Supportive Care in Cancer(IF 2.649), 2017, Vol.25 (1), pp.297-301Springer
摘要:The purpose of this review is to update the MASCC (Multinational Association of Supportive Care in Cancer) guidelines for controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
作者:... Rudolph Navari , Lee Schwartzberg , Cesare Gridelli
来源:[J].Supportive Care in Cancer(IF 2.649), 2017, Vol.25 (1), pp.85-92Springer
摘要:Addition of rolapitant to standard antiemetic therapy improved protection against chemotherapy-induced nausea and vomiting (CINV) in phase 3 trials of patients receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC). Here, we assessed the impact...
作者:Lee Schwartzberg , Kristi McIntyre ...
来源:[J].BMC Cancer(IF 3.333), 2019, Vol.19 (1), pp.1-10DOAJ
摘要:Abstract Background Eribulin mesylate is a nontaxane microtubule dynamics inhibitor approved for second-line (European Union) or third-line (United States) treatment of metastatic breast cancer. Two phase 2 single trials, evaluating first-line eribulin as monotherapy (Study ...
作者:Lee Schwartzberg , Beata Korytowsky ...
来源:[J].Clinical Lung Cancer(IF 2.038), 2019, Vol.20 (4), pp.287-296.e4Elsevier
摘要:Abstract(#br)Background(#br)The real-world effect of anti-programmed death ligand 1 (PD-L1) therapies is unclear. We compared US patients who received second-line therapy for non–small-cell lung cancer (NSCLC) before and shortly after US Food and Drug Administration (FDA) ap...
作者:... Hope S. Rugo , Lee Schwartzberg , Charles Vogel
来源:[J].Clinical Breast Cancer(IF 2.422), 2019Elsevier
摘要:Abstract(#br)Expression of human epidermal growth factor receptor 2 (HER2) in breast cancer defines a subset of patients (∼15%-20%) who are candidates for anti-HER2 therapies, most notably, trastuzumab, pertuzumab, antibody drug conjugates (eg, T-DM1), and tyrosine kinase in...
作者:Lee Schwartzberg , Erhan Berrak ...
来源:[J].Clinical Breast Cancer(IF 2.422), 2014, Vol.14 (6), pp.405-412Elsevier
摘要:Abstract(#br)Background(#br)The aim of this study was to assess efficacy and safety of eribulin with trastuzumab as first-line therapy for locally recurrent or metastatic HER2+ breast cancer.(#br)Patients and Methods(#br)In this multicenter, phase II, single-arm study, patients w...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×